Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Rasha W Al-Ali
Observed names:
Rasha Al-Ali,
Rasha W. Al-Ali
Institution:
Virginia Tech
Observed institution:
Virginia Tech
OpenAlex ID:
A5115006324
CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non–adverse-risk AML: the NCRI AML18 trial
2025
·
Steven Knapper
, Laura W. Dillon
, et al.
·
Blood
·
6
PDF
Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia
2025
·
Rasha W. Al-Ali
, Gege Gui
, et al.
·
Bone Marrow Transplantation
·
4
PDF
The MEASURE Genome Atlas: Acute Myeloid Leukemia at diagnosis and complete remission
2025
·
Kai Yu
, Laura Dillon
, et al.
·
Blood
·
1
PDF
Fnih MRD in AML Biomarkers Consortium: Evaluation of Methods for Detection of FLT3 internal Tandem Duplication Measurable Residual Disease in Acute Myeloid Leukemia
2025
·
Laura W Dillon
, Lan Beppu
, et al.
·
Transplantation and Cellular Therapy
·
1
Personalized measurable residual disease assays for acute myeloid leukemia guided by whole-genome sequencing
2026
·
Niveditha Ravindra
, Rasha W. Al-Ali
, et al.
·
Haematologica
Genomics of Acute Myeloid Leukemia at Diagnosis and Remission
2025
·
Kai Yu
, Laura W. Dillon
, et al.
·
medRxiv
Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia
2025
·
Rasha Al-Ali
, Gege Gui
, et al.
·
Transplantation and Cellular Therapy
Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia
2024
·
Rasha W Al-Ali
, Gege Gui
, et al.
·
Blood
PDF
A Randomised Comparison of CPX-351 Versus Standard Daunorubicin and Cytarabine Plus Fractionated Gemtuzumab Ozogamicin in Older Adults with AML without Adverse Risk Cytogenetics: Results of the NCRI AML18 Trial
2024
·
Steven Knapper
, Laura W Dillon
, et al.
·
Blood
PDF
Show more works
View as search
Works count:
9
Citation count:
12
H-index:
2
I10-index:
Year
Topic
Type
